APY Aspyra,

Aspyra, Inc. (AMEX:APY) today entered into a non-exclusive reseller agreement with IMIX Americas, Inc., allowing Aspyra to resell and promote IMIX๏ฟฝs Digital Radiography (DR) technology product line nationally to new and existing Aspyra Picture Archive Communications System (PACS) customers. IMIX is a manufacturer of DR systems for diagnostic use in hospitals, clinics, imaging centers and orthopedic group practices, which is the same audience Aspyra markets its clinical and imaging product solutions to. Aspyra will resell the IMIX DR technology solutions with its AccessNET๏ฟฝ and AccessMED๏ฟฝ PACS solutions. The Company๏ฟฝs AccessNET PACS is used for the management of clinical images and reports. It provides scalable PACS functionality as well as management of clinical workflow for the hospital and clinic imaging departments. AccessMED Specialty PACS is a medical imaging solution that delivers the power of a PACS, wrapped with a suite of easy-to-use viewing tools for specialists, such as orthopedic surgeons, to quickly get the information they need for decision making. ๏ฟฝWe are excited to work with Aspyra, offering combined DR and PACS solutions for new and existing customers,๏ฟฝ stated Sigrid Smitt-Jeppesen, President of IMIX. She continued, ๏ฟฝWith use of the IMIX DR technology, the customer experiences superior image quality with a highly reliable technology that offers a low initial investment and proven low maintenance costs ๏ฟฝ consistent with that of Aspyra๏ฟฝs product offerings.๏ฟฝ ๏ฟฝBy offering DR with our PACS, we can provide the customer a complete, cost-effective digital solution,๏ฟฝ states Bill Culton, Aspyra๏ฟฝs Diagnostic Solutions Product Manager. He continues, ๏ฟฝThe combined PACS/DR offering enables the healthcare organization to reduce costs, see more patients, and provide a higher level of patient care. In addition, we help the organization to be more environmentally conscious, with less film and chemical usage.๏ฟฝ The 18-month national reseller agreement became effective October 15, 2008 and is specific to IMIX DRinsight product line. Both companies will be exhibiting their products at the RSNA 2008 Annual Conference, held at the McCormick Convention Center in Chicago, November 30 ๏ฟฝ December 4, 2008. Aspyra will be at booth 6610, South Hall. IMIX will be at booth 5865, South Hall. About IMIX IMIX is a global company with a wide range of experience developing and producing Direct Digital products for medical diagnostic imaging. An early pioneer of Digital Imaging products, IMIX was originally established in Finland in 1993, initial clinical installations have been in use since 1996. IMIX DR products are designed for use in hospitals, clinics, imaging centers and orthopedic group practices. For more information on IMIX and its product solutions, visit www.imixadr.com. About Aspyra Aspyra is a global provider of Health Care Information Technology (HCIT) solutions and services to the healthcare industry. The Company specializes in Clinical Information Systems (CIS), Picture Archive Communication Systems (PACS) and Clinical Image Management Systems (CIMS) for hospitals, multi-specialty clinics, clinical laboratories, imaging departments and centers and orthopedic environments. Aspyra's highly scalable systems can be installed standalone or integrated to provide a single-vendor, enterprise-wide solution. For more information on Aspyra, its products and services, visit www.aspyra.com. Safe Harbor Statement This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not guarantees of future performance and are inherently subject to uncertainties and other factors which could cause actual results to differ materially from the forward-looking statement. Such statements are based upon, among other things, assumptions made by, and information currently available to, management as of the date of this release, including management's own knowledge and assessment of the Company's industry, customers and competition. Factors that could cause Aspyra's actual results to differ materially from these forward-looking statements include among others: changes in the Company๏ฟฝs management or other personnel, the competitive environment for Company products and services; unexpected technical and marketing difficulties inherent in major product development efforts; the potential need for changes in the Company๏ฟฝs long-term strategy in response to future developments; future advances in clinical information technology and procedures, as well as potential changes in government regulations and healthcare policies; and rapid technological change in the microelectronics and software industries. The Company refers interested persons to its most recent Annual Report on Form 10-KSB and its other SEC filings for a description of additional uncertainties and factors, which may affect forward-looking statements. The Company assumes no duty to update its forward-looking statements.